Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is essential for the growth and metastasis of tumours. One of the most important angiogenic factors is vascular endothelial growth factor (VEGF). It is upregulated by many oncogenes but especially by hypoxia via a hypoxia-regulated transcription factor called hypoxia-inducible factor 1 (HIF-1). Hypoxia is a common event found in tumours and is associated with resistance to therapy and a poor prognosis. This review describes recent advances in the regulation of gene expression, angiogenesis and tumour therapies related to hypoxia. © 2000 Ashley Publications Ltd.

Original publication




Journal article


Expert Opinion on Therapeutic Targets

Publication Date





361 - 375